RESUMEN
ObjectiveThis study analyzed the outcome indicators in randomized controlled trials （RCTs） on traditional Chinese medicine （TCM） treatment of vertigo， aiming to provide a reference for clinical trial protocol design and the establishment of core indicator sets for vertigo treatment. MethodCNKI， Wanfang， VIP， SinoMed， PubMed， Embase， and Web of Science were searched for the RCTs on TCM treatment of vertigo， and data extraction was conducted. ResultA total of 375 RCTs involving 33 593 patients were included， from which 482 outcome indicators were extracted， with a frequency of 2 715 and an average of seven outcome indicators used for each RCT. In addition， there were some differences in outcome indicators reported by different study groups. According to the functional properties， the reported outcome indicators were classified into nine domains： clinical symptoms and signs， TCM symptom efficacy， physical and chemical examinations， quality of life， mental health， safety events， patients’ satisfaction degree， long-term prognosis， and economic evaluation. The outcome indicators with higher frequency were clinical total effective rate， total TCM symptom score， occurrence of adverse reactions， dizziness handicap inventory （DHI） score， average flow velocity of the basilar artery， incidence of adverse reactions， average flow velocity of the left vertebral artery， average flow velocity of the right vertebral artery， plasma viscosity， and vertigo score. ConclusionThe outcome indicators reported by RCTs of TCM treatment of vertigo mainly have two problems： lack of unified standards and norms and insufficient attention to outcome indicators that can reflect the characteristics of TCM. The construction of the core indicator set for TCM treatment of vertigo should fully highlight the characteristic advantages of TCM and unify the standards and norms for the outcome indicators on this basis， so as to improve the quality of clinical research and the value of secondary research.
RESUMEN
Existing traditional Chinese medicine (TCM)-related databases are still insufficient in data standardization, integrity and precision, and need to be updated urgently. Herein, an Encyclopedia of Traditional Chinese Medicine version 2.0 (ETCM v2.0, http://www.tcmip.cn/ETCM2/front/#/) was constructed as the latest curated database hosting 48,442 TCM formulas recorded by ancient Chinese medical books, 9872 Chinese patent drugs, 2079 Chinese medicinal materials and 38,298 ingredients. To facilitate the mechanistic research and new drug discovery, we improved the target identification method based on a two-dimensional ligand similarity search module, which provides the confirmed and/or potential targets of each ingredient, as well as their binding activities. Importantly, five TCM formulas/Chinese patent drugs/herbs/ingredients with the highest Jaccard similarity scores to the submitted drugs are offered in ETCM v2.0, which may be of significance to identify prescriptions/herbs/ingredients with similar clinical efficacy, to summarize the rules of prescription use, and to find alternative drugs for endangered Chinese medicinal materials. Moreover, ETCM v2.0 provides an enhanced JavaScript-based network visualization tool for creating, modifying and exploring multi-scale biological networks. ETCM v2.0 may be a major data warehouse for the quality marker identification of TCMs, the TCM-derived drug discovery and repurposing, and the pharmacological mechanism investigation of TCMs against various human diseases.
RESUMEN
<p><b>OBJECTIVE</b>To compare the different gene expression profiles among Qingkailing components of BA (baicalin), JA (jasminoidin), CA (cholic acid) and CM (concha margaritiferausta) in regulating hippocampus ischemia related genes of mice.</p><p><b>METHOD</b>The hippocampus ischemia-reperfusion model mice were randomly divided into groups of BA, JA, CA, CM and M (model group), 15 mice for each group, and decapitated after 24 hours. Coronal brain slices were stained with TTC (2, 3, 5-Triphenylte trazolium Chloride) and the percentages of infarct volume were calculated. Meanwhile, total RNA were extracted from the hippocampus. We selected 374 genes which related to cerebral ischemia to find the different gene expression profiles among the Qingkailing components. Then T-tests was used to select different genes between BA and CM, JA and CM, CA and CM by Arraytrack software (P < 0. 05, Fold change > 1.5), and the pharmacodynamic characteristics were explored according to GO functional classification.</p><p><b>RESULT</b>Compared with the model group BA, JA and CA could effectively reduce infarct size of hippocampus ischemic (P < 0.05). the numbers of significantly differentially expressed genes were 41 (24 up, 17 down) between BA and CM, 22 (13 up, 9 down) between JA and CM, and 11(8 up, 3 down) between CA and CM. All of BA, JA and CA could inhibit the expression of Myb gene.</p><p><b>CONCLUSION</b>When exerting its pharmacological effects, BA, JA, CA not only have common gene targets but also have diversity in pharmacological character.</p>